{
    "clinical_study": {
        "@rank": "138007", 
        "arm_group": {
            "arm_group_label": "Indoximod and Gemcitabine + Nab-paclitaxel", 
            "arm_group_type": "Experimental", 
            "description": "Phase 1 portion:\nParticipants to receive indoximod (600mg, 100mg, or 1200mg according to their assigned dose cohort) PO BID for 28 days concurrently with IV Nab-paclitaxel 125 mg/m^2 followed by gemcitabine 1000 mg/m^2 weekly for 3 weeks with one week rest. Each cycle is 28 days. Patients will continue until they experience disease progression or significant toxicity.\nPhase 2 portion:\nOnce a RP2D is determined, treatment will commence with oral indoximod concurrent with the first backbone chemotherapy cycle.Patients will receive gemcitabine plus nab-paclitaxel on a standard 4 week cycle schedule. Oral indoximod will continue throughout."
        }, 
        "brief_summary": {
            "textblock": "This phase I/II trial is designed to efficiently identify the regimen limiting toxicity\n      (RLT) and recommended phase 2 dose (RP2D) for the combination of the immunotherapeutic agent\n      indoximod when administered in combination with standard of care chemotherapy gemcitabine\n      plus nab-paclitaxel in subjects with metastatic adenocarcinoma of the pancreas. All subjects\n      will receive the same standard gemcitabine plus nab-paclitaxel regimen, plus indoximod in\n      doses increasing from 600 mg twice daily to, potentially, 1200 mg twice daily."
        }, 
        "brief_title": "Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer", 
        "condition": [
            "Metastatic Pancreatic Adenocarcinoma", 
            "Metastatic Pancreatic Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Pancreatic Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a Phase I/II trial designed to evaluate the combination of the immunotherapeutic\n      agent indoximod and the standard of care chemotherapy gemcitabine plus nab-paclitaxel in\n      subjects with metastatic adenocarcinoma of the pancreas. The phase 1 portion is designed to\n      identify the regimen-limiting toxicity (RLT) and recommended phase 2 dose (RP2D) for the\n      combination. The phase 2 portion of the study will evaluate the potential efficacy of this\n      combination. All subjects will receive the standard 28-day gemcitabine plus nab-paclitaxel\n      regimen. Twice daily oral indoximod will be administered concurrently in continuous 28 day\n      cycles.\n\n      In the phase 1 portion, dose escalation of indoximod will begin at 600mg/day and potentially\n      escalate to 1200mg/day. There will be no intra-subject dose escalation.  Regimen-limiting\n      toxicity will be considered as those toxicities related to indoximod that significantly\n      limit the administration of the backbone chemotherapy gemcitabine plus nab-paclitaxel.  The\n      period for determination of dose-limiting toxicities will be the initial 28 days of\n      treatment.  The recommended phase 2 dose will include an assessment of toxicities that occur\n      at later time points.\n\n      Once a RP2D is determined, the phase 2 portion of the study will be initiated. In both phase\n      1 and phase 2, every 2 cycles subjects will have repeat imaging to assess response.\n      Corollary biomarkers will be assessed at the same interval as will PET-CT after the 1st 8\n      week cycle. Up to 18 patients will be enrolled in the phase 1 portion of the study and 80\n      patients will be enrolled in the phase 2 portion."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient has definitive histologically or cytologically confirmed metastatic\n             adenocarcinoma of the pancreas. The definitive diagnosis of metastatic pancreatic\n             adenocarcinoma will be made by integrating the histopathological data within the\n             context of the clinical and radiographic data. Patients with islet cell or\n             neuroendocrine neoplasms are excluded.\n\n          -  Initial diagnosis of metastatic disease must have occurred \u22648 weeks prior to entry in\n             the study.\n\n          -  Patient has one or more metastatic tumors measurable per RECIST 1.1 by CT scan \u22644\n             weeks prior to entry into the study (or MRI, if patient is allergic to CT contrast\n             media). Patients cannot have nodal metastases alone even if such nodal metastases are\n             formally considered M1 disease\n\n          -  Life expectancy of greater than 3 months.\n\n          -  Male or non-pregnant and non-lactating female, and \u226518 years of age.\n\n          -  If a female patient is of child-bearing potential, as evidenced by regular menstrual\n             periods, she must have a negative serum pregnancy test (\u03b2-hCG) documented within 7\n             days prior to the first administration of study drug.\n\n          -  The effects of indoximod on the developing human fetus are unknown. For this reason\n             and because indoximod may affect maternal immune tolerance of the fetus, sexually\n             active women of child-bearing potential must agree to use two forms of contraception\n             (hormonal and barrier method of birth control or abstinence) prior to study entry and\n             for the duration of study participation. Use of contraception or abstinence should\n             continue for a minimum of 1 month after completion of the study. Should a woman\n             become pregnant or suspect she is pregnant while participating in this study, she\n             should discontinue the study drug and inform her treating physician immediately. Also\n             men should be discouraged from fathering children while on treatment.\n\n          -  Patients must have received no previous radiotherapy, surgery, chemotherapy or\n             investigational therapy for the treatment of metastatic disease.\n\n          -  Prior treatment with gemcitabine and/or nab-paclitaxel in the adjuvant setting is\n             allowed, provided at least 6 months have elapsed since completion of the last dose\n             and no lingering toxicities are present.\n\n          -  Patients cannot have received any other immunomodulatory therapies (including\n             vaccines) as treatment for this or any other cancer.\n\n          -  Patient has adequate biological parameters as demonstrated by the following blood\n             counts at Baseline (obtained \u226414 days prior to treatment initiation):\n\n          -  Absolute neutrophil count (ANC) \u22651.5 \u00d7 10^9/L\n\n          -  Platelet count \u226575,000/mm3 (75 \u00d7 10^9/L)\n\n          -  Hemoglobin (Hgb) \u22659 g/dL.\n\n          -  Patient has the following blood chemistry levels at Baseline (obtained \u226414 days prior\n             to randomization):\n\n          -  AST (SGOT), ALT (SGPT) \u22642.5 \u00d7 upper limit of normal range (ULN), unless liver\n             metastases are clearly present, then \u22645 \u00d7 ULN is allowed\n\n          -  Total bilirubin \u2264ULN\n\n          -  Serum creatinine within normal limits or calculated clearance\u2028\u226560 mL/min/1.73 m^2 for\n             patients with serum creatinine levels above or below the institutional normal value\n\n          -  Patient has acceptable coagulation studies (obtained \u226414 days prior to randomization)\n             as demonstrated by prothrombin time (PT) and partial thromboplastin time (PTT) within\n             normal limits (\u00b115%). If the patient is on coumadin we suggest switching the patient\n             to a low molecular weight heparin product including enoxaparin (Lovenox) and\n             fondiparinux (Arixtra), but if not feasible then INR must be \u2264 3.\n\n          -  Patient has no clinically significant abnormalities in urinalysis results (obtained\n             \u226414 days prior to randomization).\n\n          -  Patient has a Karnofsky performance status (KPS) \u2265 70.\n\n          -  Patients should be asymptomatic for jaundice prior to Day 1.\n\n          -  Significant or symptomatic amounts of ascites should be drained prior to enrollment.\n\n          -  Pain symptoms should be stable and should not require modifications in analgesic\n             management prior to enrollment.\n\n          -  Ability to understand and the willingness to sign a written informed consent\n             document.\n\n        Exclusion Criteria:\n\n          -  Patients may not be receiving (or received prior to enrollment) any other\n             investigational agents for metastatic disease.\n\n          -  Patient has known brain metastases,\n\n          -  Patient has only locally advanced disease.\n\n          -  Lymph node only metastases even if considered M1 disease by official staging\n             criteria.\n\n          -  History of malignancy in the last 3 years. Patients with prior history of in situ\n             cancer or basal or squamous cell skin cancer are eligible. Patients with other\n             malignancies are eligible if they were cured by surgery alone or surgery plus\n             radiotherapy and have been continuously disease-free for at least 3 years.\n\n          -  Patient has active, uncontrolled bacterial, viral, or fungal infection(s) requiring\n             systemic therapy.\n\n          -  Patient has known historical or active infection with HIV, hepatitis B, or hepatitis\n             C.\n\n          -  Patients with any active autoimmune disease (i.e. psoriasis, extensive atopic\n             dermatitis, asthma, IBD, M.S., uveitis, vasculitis), chronic inflammatory condition,\n             or any condition requiring concurrent use of any systemic immunosuppressants or\n             steroids for any reason would be excluded from the study. Any patient with an\n             allo-transplant of any kind would be excluded as well. This would include those with\n             a xenograft heart valve to avoid the potential risk of any immune reaction causing\n             valvular degeneration. Mild-intermittent asthma requiring only occasional\n             beta-agonist inhaler use or mild localized eczema will not be excluded.\n\n          -  Patient has undergone major surgery, other than diagnostic surgery (ie, surgery done\n             to obtain a biopsy for diagnosis without removal of an organ), within 4 weeks prior\n             to Day 1 of treatment in this study.\n\n          -  Patient has a history of allergy or hypersensitivity to any of the study drugs or any\n             of their excipients.\n\n          -  Uncontrolled intercurrent illness including, but not limited to, symptomatic\n             congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or\n             psychiatric illness/social situations that would limit compliance with study\n             requirements.\n\n          -  Pregnant women are excluded from this study, breastfeeding should be discontinued."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "98", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02077881", 
            "org_study_id": "NLG2104"
        }, 
        "intervention": [
            {
                "arm_group_label": "Indoximod and Gemcitabine + Nab-paclitaxel", 
                "description": "Nab-Paclitaxel 125 mg/m^2 given intravenously over 30-40 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest. Patients will continue until they experience disease progression or significant toxicity.", 
                "intervention_name": "Nab-Paclitaxel", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Abraxane", 
                    "Paclitaxel"
                ]
            }, 
            {
                "arm_group_label": "Indoximod and Gemcitabine + Nab-paclitaxel", 
                "description": "Gemcitabine 1000 mg/m^2 given intravenously over 30 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest. Patients will continue until they experience disease progression or significant toxicity.", 
                "intervention_name": "Gemcitabine", 
                "intervention_type": "Drug", 
                "other_name": "Gemzar"
            }, 
            {
                "arm_group_label": "Indoximod and Gemcitabine + Nab-paclitaxel", 
                "description": "Indoximod will be administered in escalating doses. Initial dosing will be 600 mg BID by mouth with escalation planned to 1200 mg BID by mouth\nIndoximod in the form of 200 mg capsules will be given (3, 5, and 6 capsules depending on the escalated dose). Indoximod should be taken with water by mouth one hour before breakfast and one hour prior to dinner. The medication should be taken twice daily for 28 days each cycle. Patients will continue until they experience disease progression or toxicity.", 
                "intervention_name": "Indoximod", 
                "intervention_type": "Drug", 
                "other_name": [
                    "1-methyl-D-tryptophan", 
                    "D-1MT"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Gemcitabine", 
                "Paclitaxel"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "metastatic", 
            "metastasis", 
            "Pancreatic", 
            "Pancreas", 
            "Cancer", 
            "adenocarcinoma"
        ], 
        "lastchanged_date": "February 28, 2014", 
        "number_of_arms": "1", 
        "official_title": "A Phase I/II Study of Indoximod in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Adenocarcinoma of the Pancreas", 
        "overall_official": {
            "affiliation": "NewLink Genetics Corporation", 
            "last_name": "Nicholas Vahanian, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Phase 1 component:\nTo determine recommended phase 2 dose of indoximod when administered with a standard of care chemotherapy backbone consisting of gemcitabine plus nab-paclitaxel.", 
                "measure": "Phase 2 Dosing", 
                "safety_issue": "Yes", 
                "time_frame": "10 months"
            }, 
            {
                "description": "Phase 1 component:\nTo identify the regimen limiting toxicity (RLT) for the combination of the immunotherapeutic agent indoximod when administered in combination with standard of care chemotherapy gemcitabine plus nab-paclitaxel in subjects with metastatic adenocarcinoma of the pancreas.\nRLT will be considered as only grade 3 and 4 toxicities that are attributable to the test agent and result in the delay of the administration of the backbone chemotherapy, gemcitabine plus nab-paclitaxel.", 
                "measure": "Regimen Limiting Toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "10 months"
            }, 
            {
                "description": "Phase 2 component:\nTo evaluate efficacy as determined by overall survival (OS) in patients with metastatic adenocarcinoma of the pancreas.", 
                "measure": "Overall Survival", 
                "safety_issue": "No", 
                "time_frame": "22 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02077881"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "A secondary objective is to examine biomarker responses of gemcitabine and nab-paclitaxel with indoximod through the evaluation of serum for biomarkers of IDO activity (kynurenine and tryptophan), before and after initiation of therapy through specimen collection at protocol specified timepoints.", 
                "measure": "Biomarker Response", 
                "safety_issue": "No", 
                "time_frame": "22 months"
            }, 
            {
                "description": "To determine the response rate of the combination indoximod with gemcitabine plus nab-paclitaxel. Imaging assessments to be performed at protocol-specified time points and evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1).", 
                "measure": "Response Rate", 
                "safety_issue": "No", 
                "time_frame": "22 months"
            }, 
            {
                "description": "To determine the time to progression with the combination indoximod with gemcitabine plus nab-paclitaxel. Progression will be evaluated in this study using the new international criteria proposed by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1).", 
                "measure": "Time to Progression of Disease", 
                "safety_issue": "No", 
                "time_frame": "22 months"
            }
        ], 
        "source": "NewLink Genetics Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "NewLink Genetics Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}